1-20 of 87
peginterferon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Naranie Shanmuganathan, MBBS FRACP FRCPA, Andrew Grigg, Ilona Cunningham, MBBS FRACP FRCPA, Jake Shortt, FRACP,FRCPA,PhD, Philip Rowling, MBBS FRACP FRCPA, John Reynolds, PhD, Rosemary Anne Harrup, MBBS, FRACP, FRCPA, David M Ross, MD PhD, David Kipp, MBBS,FRCPA,FRACP, Anthony K Mills, FRACP, FRCPA, MBBS, Christopher K Arthur, MBBS FRACP FRCPA, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Kathryn Jackson, MBBS FRACP FRCPA, Nicholas Viiala, MBBS FRACP FRCPA, Robert Weinkove, MD, Agnes S. M. Yong, MD PhD, Deborah L. White, PhD FFSc (RCPA), Susan Branford, PhD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, On Behalf of the ALLG
Journal: Blood
Blood (2019) 134 (Supplement_1): 2926.
https://doi.org/10.1182/blood-2019-125740
Published: 2019
Journal Articles

UK Single Institution Experience of Mastocytosis: Guy's and St Thomas' NHS Foundation Trust

Clare Oni, MD, Mufaddal Moonim, MD, Joana Desterro, MD, Clive Grattan, MD, Natalia Curto-Garcia, MD, Claire Woodley, Monika Ciesielska, Deimante Drasutyte, Yvonne Francis, Jennifer O'Sullivan, MD, Thompson Olaoni, Anna Green, MD, Miki Yurina, MD, Mark Ong, MD, Nick C.P. Cross, Professor, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, Deepti Radia
Journal: Blood
Blood (2019) 134 (Supplement_1): 2960.
https://doi.org/10.1182/blood-2019-130477
Published: 2019
Journal Articles

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Franck E Nicolini, MD PhD, Gabriel Etienne, MD PhD, Francoise Huguet, MD, Agnès Guerci-Bresler, MD PhD, Aude Charbonnier, MD PhD, Martine Escoffre-Barbe, MD, Viviane Dubruille, MD, Hyacinthe Johnson-Ansah, MD, Laurence Legros, MD PhD, Valerie Coiteux, MD, Pascale Cony-Makhoul, MD, Pascal Lenain, MD, Lydia Roy, MD, Philippe Rousselot, MD PhD, Denis Guyotat, MD PhD, Jean-Christophe Ianotto, MD PhD, Martine Gardembas, MD, Eric Deconinck, MD PhD, Fabrice Larosa, MD, Denis Caillot, MD, Pascal Turlure, MD, Stephane Courby, MD, Philippe Quittet, MD, Eric Hermet, MD, Shanti Ame, MD, Simona Lapusan, MD, Alexandre Deloire, CRA, Stephane Morisset, BioStat, Madeleine Etienne, CRA, Delphine Rea, MD, Stephanie Dulucq, PharmD, PhD, Francois-Xavier Mahon, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 494.
https://doi.org/10.1182/blood-2019-123674
Published: 2019
Journal Articles

Nilotinib Vs Nilotinib Plus Pegylated Interferon α (Peg-IFN) Induction and Nilotinib or Peg-IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1 Positive Chronic Myeloid Leukemia Patients in Chronic Phase (TIGER Study): The Addition of Peg-IFN Is Associated with Higher Rates of Deep Molecular Response

Andreas Hochhaus, MD, Andreas Burchert, MD, Susanne Saussele, MD, Gabriela M Baerlocher, MD, Tim H Brümmendorf, MD, Paul La Rosée, MD, Dominik Heim, MD, Stefan W Krause, MD, Philipp D le Coutre, MD, Dietger Niederwieser, MD, Thoralf Lange, MD, Alice Fabarius, PhD, Mathias Hänel, MD, Frank Stegelmann, MD, Jiri Mayer, MD, Arthur Gil, MPH, Danny Himsel, MSc, Joerg Hasford, MD, Rüdiger Hehlmann, MD, Thomas Ernst, MD, Christian Fabisch, Dr.rer.MDc., Markus Pfirrmann, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 495.
https://doi.org/10.1182/blood-2019-130043
Published: 2019
Journal Articles

Prospective Evaluation of ABL Kinase Domain Mutational Analysis By Next-Generation-Sequencing in Newly Diagnosed CP CML Patients Undergoing First-Line Treatment with Nilotinib Alone or Nilotinib + Pegylated Interferon-α2a in a Prospective Phase III Trial

Hugues de Lavallade, MD PhD, Sophie Jackson, BSc, Aytug Kizilors, PhD, Gabriel Etienne, MD PhD, Francoise Huguet, MD, Agnes Guerci-Bresler, MD PhD, Delphine Rea, MD, Claudine Chollet, MSc, Stephane Morisset, BioStat, Fanny Robbesyn, BSc, Francois-Xavier Mahon, MD PhD, Stephanie Dulucq, PharmD, PhD, Franck E Nicolini, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 664.
https://doi.org/10.1182/blood-2019-125108
Published: 2019
Journal Articles

Pegylated Interferon in Myelodysplastic/Myeloproliferative Syndrome with Ringsideroblasts and Thrombocytosis

Rudolf A. Benz, MD, Kathrin Zimmermann, Corinne C Widmer, MD MSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 5433.
https://doi.org/10.1182/blood-2019-129077
Published: 2019
Journal Articles

Use of Pegylated Interferon in Six Pediatric Patients with Myeloproliferative Neoplasms

Nicole Kucine, MD, Shayla Bergmann, MD, Spencer Krichevsky, BS, Devin Jones, MS, Michael E. Rytting, MD, Linda Resar, MD, John Mascarenhas, MD, Srdan Verstovsek, MD PhD, Ronald Hoffman, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4194.
https://doi.org/10.1182/blood-2019-124023
Published: 2019
Journal Articles

Identifying Cytokine Biomarkers of Response to Pegylated-Interferon Therapy in Polycythemia Vera and Essential Thrombocythemia: Correlative Analysis from the MPN-RC 111/112 Trials

Andrew Dunbar, MD, Heidi E. Kosiorek, MS, Aishwarya Krishnan, Erin McGovern, BA, Young Park, BS, Minal A Patel, MPH, Rona Singer Weinberg, PhD, Abdulraheem Yacoub, MD, Amylou C. Dueck, PhD, John Mascarenhas, MD, Ross L. Levine, MD, Ronald Hoffman, MD, Raajit K. Rampal, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1661.
https://doi.org/10.1182/blood-2019-129571
Published: 2019
Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study

David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Andrew P. Grigg, MBBS, FRACP, FRCPA, MD, Naranie Shanmuganathan, MBBS, Ilona Cunningham, MBBS FRACP FRCPA, Jake Shortt, FRACP,FRCPA,PhD, Philip Rowling, MBBS FRACP FRCPA, John Reynolds, PhD, Rachel Cushion, Rosemary Anne Harrup, MD, David M Ross, David Kipp, MBBS,FRCPA,FRACP, Anthony K Mills, FRACP, FRCPA, MBBS, Christopher K Arthur, Anthony P Schwarer, MD MBBS(Hons), FRACP, FRCPA, Kathryn Jackson, MBBS FRACP, FRCPA, Nicholas Viiala, MBBS, FRACP, FRCPA, Robert Weinkove, MA, MBBS, PhD, FRCPath, FRACP, Agnes S. M. Yong, MD, PhD, Deborah L White, PhD, Susan Branford, PhD, Timothy P. Hughes, MD, MBBS, FRACP, FRCPA, On Behalf of the ALLG
Journal: Blood
Blood (2018) 132 (Supplement 1): 459.
https://doi.org/10.1182/blood-2018-99-110569
Published: 2018
Journal Articles

Effect of Ropeginterferon Alfa-2b in Prefibrotic Primary Myelofibrosis

Heinz Gisslinger, Bettina Gisslinger, Martin Schalling, MSc, Kurt Krejcy, PhD, Rudolf S. Widmann, PhD BSc, Robert Kralovics, PhD, Maria-Theresa Krauth, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3029.
https://doi.org/10.1182/blood-2018-99-119268
Published: 2018
Journal Articles

Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial

Ruben A. Mesa, MD FACP, Heidi E. Kosiorek, MS, John Mascarenhas, MD, Josef T. Prchal, MD, Alessandro Rambaldi, MD, Dmitriy Berenzon, MD, Abdulraheem Yacoub, MD, Claire N. Harrison, MD DM, FRCP, PRCPath, Mary Frances McMullin, MD, Alessandro M. Vannucchi, MD, Joanne Ewing, PhD BMBS, BSc, FRPATH,, Casey L. O'Connell, MD, Jean-Jacques Kiladjian, MD PhD, Adam J. Mead, MD PhD, Elliott F. Winton, MD, David S. Leibowitz, MD, Valerio De Stefano, MD, Murat O. Arcasoy, MD, Craig M. Kessler, Rosalind Catchatourian, MD, Damiano Rondelli, MD, Richard T. Silver, MD, Andrea Bacigalupo, MD, Arnon Nagler, MD, Marina Kremyanskaya, MD PhD, Lonette Sandy, Mohamed E. Salama, MD, Vesna Najfeld, PhD, Joseph Tripodi, Rona Singer Weinberg, PhD, Raajit K. Rampal, MD PhD, Ronald Hoffman, MD, Amylou C. Dueck, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3032.
https://doi.org/10.1182/blood-2018-99-111929
Published: 2018
Journal Articles

Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL+ Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study

Andreas Hochhaus, MD, Susanne Saussele, MD, Gabriela M Baerlocher, Tim H Brümmendorf, MD, Andreas Burchert, MD, Paul La Rosée, MD, Joerg Hasford, MD, Rüdiger Hehlmann, MD, Dominik Heim, MD, Stefan W Krause, MD, Philipp le Coutre, MD, Dietger Niederwieser, MD, Jiří Mayer, Thoralf Lange, MD, Mathias Haenel, MD, Frank Stegelmann, MD, Arthur Gil, MPH, Thomas Ernst, Christian Fabisch, PhD, Markus Pfirrmann, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 460.
https://doi.org/10.1182/blood-2018-99-112119
Published: 2018
Journal Articles

Synergistic Effect of Imatinib and Ruxolitinib in a Patient with JAK2 V617F positive Myelofibrosis and Concomitant BCR-ABL1 positive Chronic Myeloid Leukemia

Srinivas K. Tantravahi, MBBS, Soo Jin Kim, MS, Jeffrey A Gilreath, PharmD, Anthony D. Pomicter, MS, Tsewang Tashi, MD, Michael W. Deininger, MD PhD, Josef T. Prchal, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5482.
https://doi.org/10.1182/blood-2018-99-119745
Published: 2018
Journal Articles

Health-Related Quality of Life Outcomes in Newly Diagnosed Chronic Myeloid Leukemia Patients Treated with Dasatinib and Low Dose Pegylated Interferon

Henrik Hjorth-Hansen, MD, Satu Mustjoki, MD PhD, Ulla Olsson-Strömberg, MD PhD, Jesper Stentoft, Professor, dr.MD, Fabio Efficace, PhD, Hemming Johansson, PhD, Yvonne Brandberg, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4260.
https://doi.org/10.1182/blood-2018-99-111714
Published: 2018
Journal Articles

Predictors of Vascular Events and Disease Transformation in Chinese Patients with Myeloproliferative Neoplasms during Long-Term Follow-up

Garret MK Leung, Jamilla Li, MBBS, MRCP, Karen Tang, MBBS, MRCP, Rita Yim, Ho-Wan Ip, MBBS,FRCPA, Jason Chi Chiu So, FRCPath,MBBS, Rock Y.Y. Leung, Clarence C.K. Lam, Yok-Lam Kwong, Harinder Gill, MDFRCP,MBBS,MRCP
Journal: Blood
Blood (2017) 130 (Supplement 1): 5273.
https://doi.org/10.1182/blood.V130.Suppl_1.5273.5273
Published: 2017
Journal Articles

Nilotinib Versus Nilotinib Combined to Pegylated-Interferon Alfa 2a in First-Line Chronic Phase Chronic Myelogenous Leukemia Patients. Interim Analysis of a Phase III Trial

Franck Emmanuel Nicolini, MD PhD, Gabriel Etienne, MD PhD, Francoise Huguet, MD, Agnes Guerci-Bresler, Aude Charbonnier, MD, Martine Escoffre-Barbe, MD, Viviane Dubruille, MD, Hyacinthe Johnson-Ansah, MD, Laurence Legros, MDPhD, Valerie Coiteux, MD, Pascale Cony-Makhoul, MD PhD, Pascal Lenain, MD, Lydia Roy, MD, Philippe Rousselot, Denis Guyotat, Jean-Christophe Ianotto, MD, Martine Gardembas, MD, Fabrice Larosa, MD, Denis Caillot, MD, Pascal Turlure, MD, Stephane Courby, MD, Philippe Quittet, MD, Eric Hermet, MD, Shanti Ame, MD, Simona Lapusan, MD, Verane Schwiertz, PharmD, Stephane Morisset, Stat, Madeleine Etienne, CRA, Delphine Rea, MD PhD, Stephanie Dulucq, PhD, Francois-Xavier Mahon, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 899.
https://doi.org/10.1182/blood.V130.Suppl_1.899.899
Published: 2017
Journal Articles

Higher Rates of Molecular Response to Peg-IFNa in JAK2V617F Vs. Calr Mutant MPN Patients Are Due to JAK1-Mediated STAT1 Activation and Autoregulation

Julia Czech, Sabrina Cordua, Barbora Weinbergerova, Lijuan Han, Claudia Schubert, Tim H. Brümmendorf, MD, Jiri Mayer, Prof, MD SCs, Zdenek Racil, MD, Blanka Kubesova, MSc, Trine Alma Knudsen, MD, Anders Sørensen, Morten Holmstrøm, Lasse Kjær, MSc, PhD, Vibe Skov, MSc, PhD, Thomas Stauffer Larsen, MD PhD, Hans Carl Hasselbalch, MD Professor, DMSc, Nicolas Chatain, Steffen Koschmieder
Journal: Blood
Blood (2017) 130 (Supplement 1): 4194.
https://doi.org/10.1182/blood.V130.Suppl_1.4194.4194
Published: 2017
Journal Articles

Variance between Experts and Oncology Healthcare Providers in Managing Polycythemia Vera and Myelofibrosis: Analysis of an Online Treatment Decision Support Tool

Ryan P Topping, PhD, Michael W. Deininger, MD PhD, John Mascarenhas, MD, Ruben A Mesa, MD, Brady Lee Stein, MD, Kevin L Obholz, PhD, Jason J Everly, PharmD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2106.
https://doi.org/10.1182/blood.V130.Suppl_1.2106.2106
Published: 2017
Journal Articles

Characteristics of 809 Patients with Essential Thrombocythemia in Real-World Clinical Practice: A Chart Review Study in the United States

Jingbo Yu, PhD, Philomena Colucci, DO, MS, Dilan Chamikara Paranagama, PhD, Smitha Sivaraman, PhD, Pavel Atanasov, Becky Hanna, Jackson Tang, Shreekant V. Parasuraman, BPharm, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1636.
https://doi.org/10.1182/blood.V130.Suppl_1.1636.1636
Published: 2017
Journal Articles

Preliminary Safety and Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM)

Mark W. Drummond, PhD MD, Daniel J. DeAngelo, MD PhD, Michael W. Deininger, MD PhD, Deepti Radia, MBBS, MRCPI, FRCPath MSc, MD, Albert Thomas Quiery, MD, Elizabeth O Hexner, MD, Hongliang Shi, MS, Terri Alvarez-Diez, PhD, Erica K. Evans, PhD, Mary Ellen Healy, MS, Beni B. Wolf, MD PhD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2016) 128 (22): 477.
https://doi.org/10.1182/blood.V128.22.477.477
Published: 2016